Back |
home / stock / xair / xair message board
Subject | By | Source | When |
---|---|---|---|
https://gravityanalytica.com/protected/analyzer/XAIR-b1879d1ce0-2020-07-06. | swingingRichard | investorshub | 07/06/2020 12:53:22 AM |
Just realized that the short interest | boston127 | investorshub | 04/04/2020 3:09:13 PM |
AH is looking very good here. | boston127 | investorshub | 03/24/2020 5:43:42 AM |
Hey good looking. | boston127 | investorshub | 03/24/2020 5:18:21 AM |
Good volume. Looking to see continual | boston127 | investorshub | 03/23/2020 8:38:48 PM |
$XAIR - Good morning boston!....Looks very interesting.... | janetcanada | investorshub | 03/23/2020 12:57:43 PM |
iNO products may get the green light from FDA... | Marvy | investorshub | 03/23/2020 11:25:55 AM |
Looks like the possibility of FDA | boston127 | investorshub | 03/23/2020 10:25:21 AM |
Trying to find out why the major | boston127 | investorshub | 03/23/2020 10:04:32 AM |
Nice move today and after hours. | boston127 | investorshub | 03/21/2020 3:03:38 AM |
whytestocks: $AITB News Article - AIT Therapeutics Announces Uplisting to the Nasdaq Capital Market | whytestocks | investorshangout | 05/03/2019 12:45:40 PM |
whytestocks: $AITB News Article - AIT Therapeutics to Demonstrate NO Generator and Delivery System a | whytestocks | investorshangout | 04/23/2019 1:20:42 PM |
PoemStone: $AITB higher highs / Pr $4.95 OTC | PoemStone | investorshangout | 01/24/2019 2:55:46 PM |
News, Short Squeeze, Breakout and More Instantly...
Beyond Air Inc. Company Name:
XAIR Stock Symbol:
NYSE Market:
GARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR) ("Beyond Air" or the "Company"), a commercial stage medical ...
GARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improv...
– Ongoing Phase 1a first-in-human clinical trial continues to demonstrate proof of concept for the UNO solid tumor platform with observed early tumor responses and clinical resolution of radiation dermatitis – Phase 1a data continue to support feasibility of admini...